Gene Expression Profile Revealed Different Effects of Angiotensin II Receptor Blockade and Angiotensin‐Converting Enzyme Inhibitor on Heart Failure
暂无分享,去创建一个
H. Aburatani | S. Kudoh | I. Komuro | Y. Zou | H. Toko | T. Kohro | H. Hasegawa | M. Mizukami
[1] H. Yoshida,et al. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure , 2001, British journal of pharmacology.
[2] P. Carson. Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure. , 2000, American heart journal.
[3] H Aburatani,et al. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. , 2000, Genomics.
[4] Bertram Pitt,et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.
[5] Y. Zou,et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. , 1999, Circulation.
[6] Y. Yazaki,et al. Angiotensin II type 1A receptor knockout mice display less left ventricular remodeling and improved survival after myocardial infarction. , 1999, Circulation.
[7] C. K. Lee,et al. Gene expression profile of aging and its retardation by caloric restriction. , 1999, Science.
[8] Shokei Kim,et al. Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. , 1999, Hypertension.
[9] H. Matsubara,et al. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases. , 1998, Circulation research.
[10] T. Iwamoto,et al. Effects of renin-angiotensin system blockade and dietary salt intake on left ventricular hypertrophy in Dahl salt-sensitive rats. , 1998, Hypertension research : official journal of the Japanese Society of Hypertension.
[11] C. Johnston,et al. Preclinical pharmacology of angiotensin II receptor antagonists: update and outstanding issues. , 1997, American journal of hypertension.
[12] J. Ménard,et al. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. , 1997, Circulation.
[13] R. McKelvie,et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators. , 1997, Journal of the American College of Cardiology.
[14] O. Carretero,et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. , 1997, The Journal of clinical investigation.
[15] W. Kiowski,et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. , 1997, Circulation research.
[16] T. Unger,et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. , 1995, Pharmacological reviews.
[17] S Sasayama,et al. Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats. , 1994, The American journal of physiology.
[18] H. Drexler,et al. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. , 1994, Circulation.
[19] Therapy Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.
[20] G. Murray,et al. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators , 1993 .
[21] P. Timmermans,et al. Angiotensin II receptors and angiotensin II receptor antagonists. , 1993, Pharmacological reviews.
[22] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[23] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[24] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[25] K. Weber,et al. Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.
[26] B. Healy,et al. Angiotensin II-forming pathways in normal and failing human hearts. , 1990, Circulation research.
[27] T. Ryan,et al. Angiotensin Converting Enzyme Inhibition in Patients with Congestive Heart Failure , 1978, Circulation.
[28] W. Kannel,et al. The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.
[29] S. Oparil,et al. Newly emerging pharmacologic differences in angiotensin II receptor blockers. , 2000, American journal of hypertension.
[30] D. Lockhart,et al. Expression monitoring by hybridization to high-density oligonucleotide arrays , 1996, Nature Biotechnology.
[31] K. Swedberg,et al. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.
[32] R. D. Kennedy. Epidemiology of heart disease in old age. , 1985, Israel journal of medical sciences.